Ovid Starts Neurology Spree With AstraZeneca Deal

 
• By Alaric DeArment

The company is using proceeds from last year’s handover of its lead epilepsy program to Takeda to fuel a push in neurology development.

Epilepsy brain
Ovid announced an in-licensing deal with AstraZeneca for a library of KCC2 transporter-targeting drugs • Source: Shutterstock

More from Neurological

More from Therapy Areas